

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/532,834	02/16/2006	Jonathan Michael Blackburn	27353-513-US1	8870
35437 7590 02/06/2007 MINTZ LEVIN COHN FERRIS GLOVSKY & POPEO 666 THIRD AVENUE			EXAMINER	
			TSAY, MARSHA M	
NEW YORK, NY 10017			ART UNIT	PAPER NUMBER
			1656	
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
31 DAYS 02/06/2007		02/06/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

· · · · · · · · · · · · · · · · · · ·	Application No.	Applicant(s)
	,	BLACKBURN ET AL.
Office Action Summary	10/532,834 Examiner	Art Unit
The MAILING DATE of this communication app	Marsha M. Tsay	1656
Period for Reply	rears on the cover sheet with the	e correspondence address
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING D/ - Extensions of time may be available under the provisions of 37 CFR 1.11 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATI 36(a). In no event, however, may a reply be will apply and will expire SIX (6) MONTHS fr , cause the application to become ABANDO	ON. Itimely filed om the mailing date of this communication. NED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on 2a) This action is FINAL . 2b) This 3) Since this application is in condition for alloware closed in accordance with the practice under Expression in the practice of the	e action is non-final. nce except for formal matters, p	
Disposition of Claims		
4) Claim(s) 40-77 is/are pending in the application 4a) Of the above claim(s) is/are withdray 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 40-77 are subject to restriction and/or	wn from consideration.	
Application Papers		
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine	epted or b) objected to by the drawing(s) be held in abeyance. Stion is required if the drawing(s) is	See 37 CFR 1.85(a). objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applic rity documents have been rece u (PCT Rule 17.2(a)).	ation No ived in this National Stage
Attachment(s) 1) M Notice of References Cited (PTO-892)	4) 🔲 Interview Summ	any (PTO-413)
Notice of References Cited (P10-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mai 5) Notice of Informa 6) Other:	Date

Art Unit: 1656

DETAILED ACTION

Claims 40-77 are pending.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 40-44, 71, drawn to a Ble fusion protein and a method of purifying a ble fusion protein.

Group II, claim(s) 45-59, drawn to a probe and a method using the probe.

Group III, claim(s) 60-67, drawn to a purification media comprising a large surface to volume area comprising a target surface presenting one or more analyte capture moieties comprising an antibiotic from the bleomycin family.

Group IV, claim(s) 68-70, drawn to a method for generating soluble forms of an insoluble protein comprising the steps of i) generating a library of protein variants; and ii) selecting colonies for the presence of a soluble protein by expressing the protein as a ble fusion protein and selecting an antibiotic from the bleomycin family.

Group V, claim(s) 72-76, drawn to a method of identifying the cellular localization of a protein.

Group VI, claim(s) 77, drawn to a kit for the production of an array comprising a ble vector and a surface derivatized with an antibiotic from the bleomycin family.

The inventions listed as Groups I-VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical feature linking Groups I-VI appears to be that they all relate to a Ble (fusion) protein which is able to bind to the bleomycin family of antibiotics.

Art Unit: 1656

However, Bennett et al. (1998 Biotechniques 24(3): 478-482) teach a Ble fusion protein. Green fluorescent protein (GFP) and the Sh ble gene were fused together to create a bifunctional protein.

Therefore, the technical feature linking the inventions of Groups I-VI does not constitute a special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art.

Accordingly, Groups I-VI are not so linked by the same or corresponding special technical feature as to form a single general inventive concept.

Further, this application contains claims directed to the following patentably distinct species: antibiotics from the bleomycin family, i.e. bleomycin, phleomycin, tallysomycin, pepleomycin, Zeocin, bleomycin A2, etc. The species are independent or distinct because each antibiotic is structurally different and has different properties and effects. These species are deemed to lack unity of invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. Currently, claims 46-47, 58-59, 64-65 are generic.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Art Unit: 1656

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marsha M. Tsay whose telephone number is 571-272-2938. The examiner can normally be reached on M-F, 9:00am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Kathleen Kerr Bragdon can be reached on 571-272-0931. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR

Art Unit: 1656

Page 5

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

February 1, 2007

MARYAM MONSHIPOURI, PH.D. PRIMARY EXAMINER